Methods for predicting anti-cancer response
First Claim
Patent Images
1. A method for administering anti-cancer treatment comprising a PARP inhibitor to a human patient, the method comprising:
- (1) assaying DNA in or derived from a hyperproliferative cell sample to(a) detect copy number at a plurality of polymorphic chromosomal loci, wherein the plurality of polymorphic chromosomal loci comprises at least 1,000 polymorphic chromosomal loci and wherein there is at least one polymorphic chromosomal locus located on average every 500 kb within each chromosome; and
(b) detect, based on the copy number detected in (a), allelic imbalance regions having a minimum segment size of 12 Mb that extend to and involve the telomere and do not cross the centromere;
(2) calculating a test global chromosomal aberration score (GCAS) for the hyperproliferative cell sample determined by summing the total number of allelic imbalance regions detected in (1)(b);
(3) detecting a global chromosomal aberration score of at least 8; and
(4) administering anti-cancer treatment comprising a PARP inhibitor to the human patient.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
-
Citations
22 Claims
-
1. A method for administering anti-cancer treatment comprising a PARP inhibitor to a human patient, the method comprising:
-
(1) assaying DNA in or derived from a hyperproliferative cell sample to (a) detect copy number at a plurality of polymorphic chromosomal loci, wherein the plurality of polymorphic chromosomal loci comprises at least 1,000 polymorphic chromosomal loci and wherein there is at least one polymorphic chromosomal locus located on average every 500 kb within each chromosome; and (b) detect, based on the copy number detected in (a), allelic imbalance regions having a minimum segment size of 12 Mb that extend to and involve the telomere and do not cross the centromere; (2) calculating a test global chromosomal aberration score (GCAS) for the hyperproliferative cell sample determined by summing the total number of allelic imbalance regions detected in (1)(b); (3) detecting a global chromosomal aberration score of at least 8; and (4) administering anti-cancer treatment comprising a PARP inhibitor to the human patient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
Specification